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ABSTRACT
Background
In heart failure (HF) with reduced ejection fraction (HFrEF), randomized controlled trials have provided 
effective treatments, but prognosis still remains poor. HF with mid-range EF (HFmrEF) has no evidence-
based therapy and represents a newly characterized and relevant population for future trials. Trials in HF with 
preserved EF (HFpEF) have failed to provide any effective treatment, with several concerns about their design.
Aims
Overall aim is to provide evidence to improve trial design in HF, investigating the use of natriuretic peptides 
(NPs) as surrogate endpoint, and as eligibility criterion to foster the enrichment of trials for cardiovascular 
(CV) vs. non-CV events. Specific aims were: 
•	 to assess the associations between changes in NP [B-type NP (BNP) and N-Terminal pro-BNP (NT-
proBNP)] levels over time and prognosis in chronic HFpEF and HFmrEF (Study I) and in acute 
decompensated HFpEF (Study II);
•	 to compare levels, the independent determinants of levels and the prognostic role of NT-proBNP across 
EF categories (Study III); 
•	 to evaluate the associations between NT-proBNP and CV and non-CV outcomes across EF categories 
and in specific subgroups, and the associations between HF therapies and outcomes according to NT-
proBNP levels (Study IV).
Changes in NT-proBNP and prognosis in chronic HFpEF and HFmrEF
We studied 650 HFpEF/HFmrEF outpatients enrolled in the Swedish Heart Failure registry (SwedeHF) 
between 2000 and 2012, reporting serial NT-proBNP assessments. A reduction in NT-proBNP at the median 
time of 7 months from the first measurement was associated with a reduction of mortality/HF hospitalization 
risk by 54% in the overall population, by 51% in HFpEF and by 61% in HFmrEF.
Changes in BNP/NTproBNP levels and prognosis in acute decompensated HFpEF
From the Karolinska-Rennes (KaRen) study, 361 patients with acute decompensated HFpEF and BNP/NT-
proBNP measurements at the baseline and at the 4-8 weeks follow-up visit were analyzed. Changes in NPs 
from baseline to follow-up visit were not significantly associated with the risk of mortality/HF hospitalization 
although a trend toward a reduction in risk following the reduction in levels was observed.
Levels, predictors of levels and prognostic/discriminatory role of NT-proBNP across EF categories
We analyzed 9,847 outpatients with HFpEF (18%), HFmrEF (22%) or HFrEF (60%) with at least one NT-
proBNP assessment, enrolled in the SwedeHF between 2000 and 2012. NT-proBNP levels were significantly 
higher in HFrEF (2,288 pg/ml) vs. HFpEF (1.428 pg/ml) and HFmrEF (1,540 pg/ml). Across EF categories, 
there were several different independent determinants for NT-proBNP levels, with atrial fibrillation more 
important in HFmrEF and HFpEF, diabetes and hypertension in HFmrEF, and age and body mass in HFrEF 
and HFmrEF, whereas there were no differences for renal function, New York Heart Association class, heart 
rate and anemia. NT-proBNP >vs. ≤median was associated with increased risk of mortality and mortality/
hospitalization with hazard ratios significantly higher in HFmrEF and HFpEF vs. HFrEF. NT-proBNP had 
greater area under the curve for death/HF hospitalization in HFmrEF vs. HFpEF and HFrEF.
NT-proBNP levels and risk of CV/non-CV events across EF categories
We studied 15,849 patients with HFpEF (23%), HFmrEF (21%) and HFrEF (56%) and at least one NT-proBNP 
assessment, enrolled in SwedeHF between 2000 and 2012. Increasing NT-proBNP levels were associated 
with a steeper increase in CV vs. non-CV event rates in HFpEF vs. HFmrEF vs. HFrEF. CV to non-CV event 
ratio increased together with the increase in NT-proBNP in HFpEF and HFrEF, but only in the lower range in 
HFmrEF. The association between HF treatments (angiotensin converting enzyme inhibitors or angiotensin 
receptor blockers and beta-blockers) and CV/non-CV events risk was consistent in NT-proBNP ≤ and >median.
Conclusions
The association between NT-proBNP levels and prognosis across the EF spectrum, together with the association 
between reduction in NT-proBNP levels and improvement in prognosis in HFpEF, HFmrEF and HFrEF 
supports the use of NT-proBNP as surrogate endpoint in phase II trials in chronic HF. We did not observe any 
significant association between changes in BNP/NT-proBNP and prognosis in acute decompensated HFpEF. 
The observed relationship between NT-proBNP levels and CV and non-CV events supports the use of NT-
proBNP for eligibility and enrichment for CV events in HF trials, but the cut-off levels should consider the 
differences in comorbidities across the EF spectrum. Potential treatment response according to NT-proBNP 
levels deserves further investigation.
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INTRODUCTION
Global burden
Heart failure (HF) represents a global pandemic. Worldwide, around 26 million people are 
affected by HF. The prevalence of the disease reports geographical differences, ranging 1-2% 
in Western countries and Australia, and reaching 1.3-6.7% in Asia, but is even expected to rise 
following the global aging of population. Incidence ranges 0.1-0.4% in Western Countries, 
approximating 1% in China 1. HF is the most common cause of hospitalization among >65 
years adults in the United States (US) 2 and even in the overall population 3. In 2012 health 
expenditure for HF approximated $31 billion and projections show that by 2030 the total cost 
of HF will increase by 127% to around $70 billion, corresponding to $244 for every US adult 
4. Prognosis is still poor, with <50% 4-year survival, similar to the most common cancers, 
and low quality of life 5, 6.
Definition
From a physiological perspective, HF can be defined as a clinical syndrome characterized by 
the reduced ability of the heart to pump (systolic dysfunction) or fill (diastolic dysfunction) 
with blood, that leads to an inadequate cardiac output to meet metabolic needs, or to a 
preserved cardiac output due to compensatory mechanisms (manifest as increased left 
ventricular filling pressures) 7. Indeed, neurohormonal activation sustains cardiac output at 
the early stages of HF, but causes progressive maladaptive cardiac remodeling leading to 
full-blown HF in the long term 8.
From a more clinical perspective, HF has been well defined in the current European Society 
of Cardiology (ESC) guidelines on HF as a clinical syndrome characterized by typical 
symptoms (e.g. breathlessness, ankle swelling and fatigue) and signs (e.g. elevated jugular 
venous pressure, pulmonary crackles and peripheral edema), caused by structural and/
or functional cardiac abnormalities, resulting in a reduced cardiac output and/or elevated 
intracardiac pressures at rest or during stress 9.
Notably, left ventricular ejection fraction (EF), which is a particularly important parameter 
in clinical practice and has been used as inclusion criterion for randomized controlled 
trials in the HF setting, does not contribute to the overall definition of HF but is key for 
characterizing the HF population. Indeed, according to EF and other additional criteria, 
HF can be classified as 1) HF with preserved EF (HFpEF) and 2) HF with mid-range EF 
(HFmrEF), characterized by EF≥50% and EF=40-49%, respectively, together with elevated 
levels of natriuretic peptides (NPs) and the presence of relevant structural heart disease (left 
ventricular hypertrophy and/or left atrial enlargement) or diastolic dysfunction; 3) HF with 
reduced EF (HFrEF), characterized by EF<40% 9. The old HF classification into systolic and 
diastolic HF has been abandoned since both systolic and diastolic dysfunction coexist, even 
though at different extent, throughout the EF spectrum 10, 11.
Another classification of HF considers the different onset of symptoms. Thus, patients may 
suffer of chronic or acute decompensated HF (ADHF), where ADHF refers to a rapid onset 
of or a progressive worsening of HF symptoms/signs in a patient with chronic HF 9. 
Gianluigi Savarese
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Etiology, risk factors and clinical characteristics
There are geographical differences for HF etiologies 1. Overall, predominant cause of HF is 
hypertension in HFpEF and ischemic heart disease in HFmrEF and HFrEF 9. Other causes 
may be cardiomyopathies, toxic damage (e.g. drug abuse, medications, radiation), abnormal 
loading conditions (e.g. valvular and pericardial diseases, severe anemia, sepsis, renal 
failure), arrhythmias, infiltrative diseases (e.g. amyloidosis, sarcoidosis, hemochromatosis) 
and metabolic derangements (e.g. thyroid disease, growth hormone deficiency) 9. Important 
risk factors for HF are age, male sex, hypertension, left ventricular hypertrophy, ischemic 
heart disease, diabetes mellitus, valvular disease, overweight/obesity, smoking and atrial 
fibrillation 12. Around 60% of the HF population has HFrEF, 20% has HFmrEF and 20% 
has HFpEF 13. In HFpEF vs. HFmrEF vs. HFrEF patients are older, more likely females and 
overweight/obese, no smokers, with higher arterial blood pressure and more likely to have 
history of hypertension, atrial fibrillation, lung disease, renal disease and anemia. Those with 
HFrEF and HFmrEF vs. HFpEF are less likely to be diabetic and have valvular disease but 
more likely to report history of coronary artery disease 13, 14. 
Pathophysiology
HFrEF
In HFrEF, the key is a direct cardiomyocyte injury 15, 16. This triggers compensatory 
neurohormonal mechanisms, such as:
•	 the activation of the sympathetic nervous system that initially contributes to main-
tain cardiac output increasing heart rate and myocardial contractility;
•	 the activation of renin-angiotensin-aldosterone system that fosters an increase in 
systemic vascular resistance and fluid reabsorption in the kidneys (by the antidiuretic 
hormone), supporting arterial blood pressure.
All these mechanisms are compensatory at the early stages of HF, but later become 
maladaptive leading to adverse cardiac remodeling (left ventricular dilatation and eccentric 
hypertrophy) and further worsening of cardiac function (Figure 1,2).
HFpEF
In HFpEF, the key is endothelial dysfunction 15, 17. Comorbidities (e.g. hypertension, diabetes, 
chronic kidney disease, anemia, chronic obstructive pulmonary disease, obesity) induce 
microvascular inflammation and thus, endothelial activation 17. Low availability of nitric oxide 
and cyclic guanosine monophosphate adversely affects the adjacent cardiomyocytes leading 
to increased myocardial stiffness, and induces the endothelial-mesenchymal transition leading 
to enhanced fibrosis 17. All these mechanisms foster concentric left ventricular remodeling 17 
(Figure 2). Neurohormonal activation is also involved in HFpEF but at a smaller extent as 
compared with HFrEF 18.
Figure 2 reports the paradigms for pathophysiology in HFpEF vs. HFrEF.
Natriuretic peptides
Secretion of NPs represents one of the compensatory mechanisms in HF. The family of 
NPs consists of three peptides: A-type (ANP), B-type (BNP) and C-type NP (CNP). ANP 
is secreted by atrial myocardium secondary to its dilatation. Similarly, BNP is secreted by 
         Natriuretic peptides for trial design in HF
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Figure 1. Compensatory mechanisms in early heart failure. 
Reproduced with permission from 16. Copyright Springer Nature. SNS: sympathetic 
nervous system; RAAS: renin-angiotensin-aldosterone system.
Figure 2. Paradigm for pathophysiology in HFpEF vs. HFrEF. 
Reproduced with permission from 15. Copyright BMJ Publishing Group Ltd. NO: 
nitric oxide; cGMP: cyclic guanosine monophosphate; HFpEF: heart failure with 
preserved ejection fraction; HFrEF: heart failure with reduced ejection fraction.
Gianluigi Savarese
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the ventricular myocardium in response to elevated end-diastolic pressure/volume. CNP is 
secreted by endothelial cells exposed to shear stress. The amount of NP secreted is directly 
correlated with the magnitude of the stress 19.  BNP has been particularly investigated in 
HF. Following the increase in ventricular end-diastolic pressure/volume that characterizes 
HF, the gene encoding BNP is transcribed and the derived mRNA translated into a 134 
amino acid length pre-pro-hormone, which is cleaved by a neutral endopeptidase into a 108 
amino acid pro-hormone, the proBNP, and a 26 amino acid peptide. Then, when secreted, 
proBNP is further cleaved by the convertase corin into a biologically active 32 amino acid 
C-terminal fragment (BNP) and a biologically inactive 76 amino acid N-terminal fragment 
(NT-proBNP) 19, 20. BNP reduces preload promoting the shifting of intravascular fluid into the 
extravascular compartment, increasing venous capacitance, fostering natriuresis that reduces 
extracellular fluid retention, and diuresis. Additionally, it reduces sympathetic tone in the 
peripheral vasculature and suppresses renin-angiotensin-aldosterone system (Figure 3) 19, 21.
Figure 3. The ABC of natriuretic peptides. 
Reproduced with permission from 21. Copyright Massachusetts Medical Society.
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BNP and NT-proBNP are useful tools for the management of HF patients, with NT-proBNP 
more used than BNP over the last years because of its longer half-time (120 vs. 20 mins 
respectively) 22. Indeed, because of their high negative predictive value, current HF ESC 
guidelines suggest to measure BNP or NT-proBNP in order to potentially exclude the 
diagnosis of HF in a patient with clinical history/symptoms/signs/ECG suggesting HF 9. 
Additionally, BNP and NT-proBNP blood levels correlate with New York Heart Association 
(NYHA) class, EF, left ventricular end-diastolic and pulmonary artery wedge pressure, and 
there is data supporting their use for hospital stay/discharge decision making 23-26. Finally, in 
HFrEF, but also to a less extent in HFpEF, there is evidence supporting the role of BNP/NT-
proBNP as predictors of clinical events 27-32. 
1-year mortality and prognosticators
One-year mortality shows geographical differences, ranging 22-37% in North America 
and 8-17% in Europe 1, 13. Differences in prognosis across HFpEF, HFmrEF and HFrEF are 
difficult to investigate, in particular because of the inconsistent definitions of HFpEF and 
HFmrEF used in different studies, but the general impression is that crude 1-year mortality 
rates are higher in HFrEF vs. HFmrEF vs. HFpEF, whereas in some studies, but not in others, 
differences disappear after adjustments for confounders 13, 33, 34.
Independent predictors of 1-year mortality regardless of EF are older age, NYHA class and 
chronic kidney disease. Body mass index is associated with mortality risk in HFrEF and 
HFpEF, low systolic blood pressure and high heart rate in HFmrEF and HFrEF and atrial 
fibrillation in HFpEF 35.
Treatments in HF
HFrEF (Figure 4)
Over the last years several treatments have been demonstrated to be effective in reducing 
mortality/morbidity in HFrEF. Inhibition of the renin-angiotensin-aldosterone system and 
the blockade of sympathetic nervous system represent the foundation of HF therapy. In the 
CONSENSUS and SOLVD trials angiotensin converting enzyme inhibitor (ACE-I) therapy 
vs. placebo reduced mortality by 27% in NYHA class IV and by 16% in NYHA class II-III, 
respectively 36, 37. 
Later in 1990s, the MERIT-HF, COPERNICUS and CIBIS II trials reported a 34-35% 
mortality reduction in patients randomized to beta-blockers vs. placebo 38-40.
At the beginning of 2000s, in the Val-HeFT and in the CHARM-Alternative trials, valsartan 
and candesartan, two angiotensin receptor blocker (ARB), significantly reduced mortality/
morbidity vs. placebo in NYHA class II-IV and in patients intolerant to ACE-I, respectively 
41, 42. Spironolactone first and later eplerenone, two mineralocorticoid receptor antagonist 
(MRA), have been shown to reduce mortality by 30% in NYHA III-IV and by 24% in NYHA 
II vs. placebo on top of other HF treatments in the RALES and EMPHASIS-HF trials, 
respectively 43, 44. Recently, in the PARADIGM-HF trial, the angiotensin receptor–neprilysin 
inhibitor LCZ696 has been tested vs. enalapril 45. This new drug, consisting of the combination 
of the neprilysin inhibitor sacubitril and the ARB valsartan, blocks at the same time the renin-
angiotensin system and inhibits neprilysin, a neutral endopeptidase that degrades several 
endogenous vasoactive peptides, including NPs. As result, BNP levels increase leading to the 
beneficial effects already discussed. In PARADIGM-HF, LCZ696 vs. enalapril significantly 
reduced mortality by 16% on top of all the other current HF treatments 45. 
Gianluigi Savarese
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Beyond pharmacological treatments, device therapies have been demonstrated to be beneficial 
in HFrEF. HFrEF patients are at risk of arrhythmia-related sudden death. Implantable 
cardioverter defibrillators (ICDs), able to identify and treat life threatening arrhythmias, have 
been shown to further reduce mortality by 31% in the MADIT-II trial enrolling patients 
with prior myocardial infarction and EF≤30%, and by 23% in SCD-HeFT enrolling patients 
with NYHA class II-III and EF≤35% 46, 47. Cardiac resynchronization therapy (CRT) has 
been demonstrated to reduce electric dyssynchrony that is often observed in HFrEF, fostering 
reverse remodeling and thus, decreasing left ventricular volumes by a synchronous pacing 
of left and right ventricles. In randomized controlled trials, CRT has been shown to improve 
quality of life, NYHA class, hospitalization by 37% and mortality by 22% 48. The benefit of 
combining ICD and CRT is still debated. Indeed, MADIT-CRT trial reported a significant 
reduction of mortality/HF events in NYHA class I-II HFrEF patients randomized to CRT-ICD 
vs. ICD alone 49, whereas in the DANISH trial ICD significantly reduced the risk of sudden 
death but not the primary outcome (all-cause death) in a non-ischemic HFrEF population 
including patients with CRT (53%) 50. 
Figure 4. Trials in heart failure with reduced ejection fraction. 
Reproduced with permissions from 56. Copyright Oxford University Press.
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In patients with HFrEF refractory to pharmacological and device treatments, heart 
transplantation still represents the gold standard. However, over the last years, due to 
shortage of organs, left ventricular assist devices (LVADs) have been used as bridge to the 
transplantation, or as bridge to candidacy, or as bridge to recovery or as destination therapy 
51. The use of LVAD is supported by the REMATCH trial that reported a 48% reduction in 
risk of mortality vs. medical therapy in NYHA class IV patients 52. Advances in technology 
have led to further improvements in prognosis in terms of survival free of adverse events in 
patients with LVAD. Continuous flow pumps (HeartMate II) have been shown to be superior 
to pulsatile flow pumps (HeartMate XVE) in patients ineligible for transplantation 53, fully 
magnetically levitated centrifugal-flow pumps (HeartMate III) superior to axial-flow pumps 
(HeartMate II) in patients receiving LVAD as bridge to transplantation or destination therapy 
54, and no differences between the axial-flow pump (HeartMate II) and the centrifugal-flow 
pump (Heartware) have been shown in patients receiving LVAD as destination therapy 55.
HFpEF
Randomized trials in HFpEF have not been as successful as in HFrEF. Thus, currently there 
is no established treatment for HFpEF patients. Indeed, in the CHARM-Preserved trial 
enrolling patients with NYHA class II-IV and EF≥40%, candesartan vs. placebo failed to 
reduce the primary outcome consisting of the composite of cardiovascular (CV) death or HF 
hospitalization, but fewer patients in the candesartan than in the placebo group were admitted 
to hospital for HF 57. Similarly, in I-PRESERVE, enrolling patients with NYHA class II-IV, 
EF≥45% and age≥60 years, irbesartan failed to reduce the primary outcome (death or CV 
hospitalization) or any secondary outcome 58. Also perindopril vs. placebo in the PEP-CHF 
trial did not reduce the risk of mortality/HF hospitalization in patients aged ≥70 years, with 
diastolic dysfunction and treated with diuretics 59. Finally, in the TOPCAT trial enrolling 
patients with symptomatic HF and EF≥45%, spironolactone vs. placebo did not reduce the 
primary outcome of the study (CV death, aborted cardiac arrest, or HF hospitalization), but 
reduced the risk of HF hospitalization by 17% 60. 
HFmrEF
HFmrEF has emerged only recently as an independent entity 9, and thus, currently it has 
no evidence-based therapy. The CHARM program evaluated the efficacy of candesartan 
in symptomatic HF across the whole EF spectrum. Recently, a post-hoc analysis analyzing 
CHARM data reported higher risk of CV death/HF hospitalization in HFmrEF and HFrEF vs. 
HFpEF with candesartan significantly reducing the risk of events in HFrEF and HFmrEF but 
not in HFpEF (in absence of any statistical interaction between EF category and candesartan 
treatment effect) 61. Additionally, in PARADIGM-HF, enrolling patients with EF≤40% sacubitril/
valsartan was effective to reduce CV death/HF hospitalization throughout the EF spectrum 62, 
whereas in TOPCAT (EF≥45%) there were signals for potential efficacy of spironolactone at 
lower EF 63. These evidences might suggest an effect for these drugs in HFmrEF.
ADHF
As in HFpEF, there are no treatments improving outcomes in ADHF, thus current HF ESC 
guidelines recommend inotropic agents (only in patients symptomatically hypotensive or 
hypoperfused), vasodilators, vasopressors and diuretics only for symptom relief with class/
level of evidence I-II/B-C 9.
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Serelaxin and ularitide have been recently tested in ADHF. Serelaxin, a recombinant human 
relaxin-2, is a naturally occurring peptide contributing to the maternal adaptations to pregnancy. 
It has been shown to increase arterial compliance, cardiac output and renal blood flow that are 
beneficial effects for ADHF patients 64. Ulartide is a chemically synthesized analogue of the 
naturally occurring vasodilator urodilatin, with hemodynamic effects that may be relevant 
in ADHF 65. Although encouraging signals for improved outcome had been observed in the 
phase 2 trial RELAX-AHF, the phase 3 trial, RELAX-AHF-2, enrolling ADHF patients 
within 16 hours from presentation to 48-hour intravenous infusions of serelaxin or placebo, 
failed to demonstrate any effect of the treatment on the primary outcomes of the study (180-
day CV death and worsening HF through day five) 66. Similarly, in the TRUE-AHF trial, 
randomizing ADHF patients to receive ularitide vs. placebo for 48 hours starting within 12 
hours from the hospital admission, ularitide failed to reduce the coprimary outcomes (CV 
death; a hierarchical composite end-point evaluating the initial 48-hour clinical course) 65.
Failure of trials in HF
Trials in HFrEF have provided several drugs and devices that significantly improve survival/
morbidity. HFmrEF has currently no evidence-based therapy yet, since it has emerged very 
recently as an independent HF phenotype and its characterization is ongoing.  Previously, 
HFmrEF patients have been enrolled inconsistently in HFpEF or HFrEF trials. Potential 
treatments have been unsuccessfully tested in HFpEF and ADHF that still lack treatments 
able to significantly improve clinical outcomes. 
What are the reasons for failure of trials in HFpEF and ADHF? Some of the explanations 
could be: 
•	 wrong treatments/doses: neurohormonal antagonists may not work in HFpEF; short-
term infusion of a pharmacological compound may not be able to reduce long-term 
outcome in ADHF; treatments for chronic HF may be not effective in ADHF 
•	 wrong patient selection: in HFpEF trials patients may not have had HFpEF or may 
have had HFpEF but poorly enriched (meaning low risk of CV events or high risk of 
non-CV events, that make testing new HF therapies ineffective or requiring exces-
sive sample size); ADHF encompasses multiple syndromes, thus it is very unlikely 
that the same drug will be effective in all patients with ADHF (“one size fits all” 
approach)
•	 wrong outcomes: including extra components in the primary outcome, although in-
creasing the number of events, may merely contribute to generate random noise, 
diluting a potential effect of the treatment; wrong surrogate endpoints may lead to 
positive phase II trials but to the failure of the following phase III trial
•	 wrong trial conduct: e.g. in TOPCAT spironolactone significantly reduced the pri-
mary outcome in Americas, but not in Georgia/Russia where canrenone concentra-
tion, a metabolite of spironolactone, was undetectable in 30% of the patients inves-
tigated, leading to hypothesize misconduct in the trial or compliance issues 67, 68; in 
TRUE-AHF, 17% of the patients did not meet entry criteria and 63% of the sites in 
the Czech Republic, Estonia, Poland, and Serbia had 3 or more ineligible patients.
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AIMS
Against this background, the overall aim is to provide evidence to improve trial design in 
HF, investigating the potential use of NPs as surrogate endpoint, and as eligibility criterion to 
foster the enrichment of trials for CV vs. non-CV events.
Specific aims are:
1. to evaluate whether a reduction of NT-proBNP levels over time is associated with 
improved prognosis in chronic HFpEF and HFmrEF (Study I)
2. to evaluate whether a reduction of NP levels (BNP or NT-proBNP) over time is 
associated with improved prognosis in acute decompensated HFpEF (Study II)
3. to compare NT-proBNP levels, to assess the independent determinants of high NT-
proBNP levels, and to compare the prognostic role and discriminatory power of 
NT-proBNP levels in HFpEF vs. HFmrEF vs. HFrEF (Study III)
4. to evaluate in HFpEF, HFmrEF and HFrEF, and in relevant subgroups 1) the 
association between NT-proBNP and CV and non-CV outcomes, 2) the association 
between HF treatments and CV and non-CV outcomes according to NT-proBNP 
levels (Study IV)
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PATIENTS AND METHODS
A summary of data and statistical methods used in the four studies is summarized in Table 1.
Table 1. Overview of data used in the thesis. 
SwedeHF: Swedish heart failure registry; EF: ejection fraction; BNP: B-type natriuretic 
peptide; N-terminal B-type natriuretic peptide; HF: Heart failure; ROC: Receiver operating 
curves; KaRen: Karolinska-Rennes.
Study I II III IV
Data source SwedeHF KaRen SwedeHF SwedeHF
Time of data 
collection
2000-2012 2007-2011 2000-2012 2000-2012
Study population EF≥40%, 
outpatient, 2 
consecutive 
NT-proBNP 
measurements, 
follow-up ≥1 day
2 consecutive 
BNP/NT-proBNP 
measurements
Known EF, 
at least 1 
NT-proBNP 
measurement, 
outpatient, follow-
up >1 day
Known EF, at least 
1 NT-proBNP 
measurement, 
follow-up >1 day
Design Registry based Prospective 
cohort
Registry based Registry based
Number of patients 650 361 9,847 15,849
Outcomes All-cause 
mortality, HF 
hospitalization, 
their composite
All-cause 
mortality, 
composite 
of all-cause 
mortality and HF 
hospitalization
All-cause 
mortality, 
composite 
of all-cause 
mortality and HF 
hospitalization
CV events, non-
CV events
Adjustments 17 variables 
significantly 
associated with at 
least 1 outcome 
at the univariate 
analysis
10 variables 
significantly 
associated with at 
least 1 outcome 
at the univariate 
analysis
32 variables 39 variables
Main statistical 
analysis
Kaplan Meier, Cox 
regression
Kaplan Meier, Cox 
regression
Logistic 
regression, 
Kaplan Meier, Cox 
regression,
ROC curves
Poisson 
regression, 
Kaplan Meier, Cox 
regression
Data Source
Studies I, III and IV – the Swedish Heart Failure Registry (SwedeHF)
For Studies I, III and IV, data from the SwedeHF have been analyzed. 
SwedeHF (www.SwedeHF.se) is a nationwide continuous health quality and research 
registry created in 2000, with widespread use in Sweden since 2003. The only inclusion 
criterion is clinician-judged HF. The EF variable is not required but it is available in ~90% 
of the registrations. Pediatric patients are excluded. Approximately 80 variables are entered 
at hospital discharge or after out-patient clinic visit into a web-based case report form. 
The Uppsala Clinical Research Center, Uppsala, Sweden (www.UCR.UU.se) manages the 
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database. The coverage of SwedeHF (calculated as all the unique patients with an echo 
assessment available registered from 2014, divided by all the patients hospitalized in Sweden 
in 2014 with a primary discharge diagnosis of HF) according to the last annual report published 
in 2015 was 54%. Active centers, defined as hospitals with more than 10 registrations/year, 
are considered for the calculation. The coverage in primary care is lower, only 12%, but 
only few patients are followed-up exclusively in primary care and are, therefore, caught and 
registered in cardiology and internal medicine departments. By the end of 2015, more than 
70,000 unique patients were registered in SwedeHF.
We matched data from SwedeHF with the Population Registry, the Patient Registry and 
Statistics Sweden by the personal identification number that all permanent residents in 
Sweden have regardless of citizenship.
The Swedish Board of Health and Welfare (www.socialstyrelsen.se) administers the 
Population Registry that provided the date of death, and the Patient Registry that supplied 
baseline comorbidities beyond those available in SwedeHF, hospitalizations and their causes, 
defined according to ICD-10 codes in the first position, and causes of death (where we used 
underlying cause rather than immediate mode of death).
Socioeconomic data were obtained by Statistics Sweden (www.scb.se). 
Study II – the Karolinska-Rennes (KaRen) study
KaRen was a prospective, multicenter study including 11 centers in France and 3 centers in 
Sweden. Patients presenting with acute signs and symptoms of HFpEF were enrolled. The 
main purpose of KaRen was to test the prognostic value of electrical and/or mechanical 
dyssynchrony in HFpEF after a follow-up of 18 months. No investigational intervention was 
tested and all patients were treated according to the standard of care. Inclusion criteria, to be 
established within 72 h of hospital presentation, were: 1) acute presentation to the hospital 
with clinical signs and symptoms of HF, according to the Framingham criteria; 2) BNP >100 
pg/ml or NT-proBNP >300 pg/ml; 3) EF≥45% by echocardiography within the first 72 h. 
Key exclusion criteria were: evidence of primary restrictive or obstructive cardiomyopathy or 
pericardial constriction, known cause of right HF not related to left ventricular dysfunction, 
renal disease requiring dialysis, pulmonary disease requiring chronic supplemental oxygen, 
existing cardiac resynchronization therapy, any CV disorder with indication for surgical or 
percutaneous intervention. Extensive baseline variables including symptoms, signs, laboratory 
and echocardiographic parameters and information about medications were assessed by local 
investigators at the time of the acute hospital presentation and when the patient returned in 
stable condition 4-8 weeks after enrollment for the follow-up visit. 
Study I
Aim
To evaluate whether a reduction of NT-proBNP levels over time is associated with improved 
prognosis in chronic HFpEF and HFmrEF.
Patients
In SwedeHF, between May 11th 2000 and December 31th 2012, 80,772 registrations were 
recorded from 51,060 unique patients. A number of 650 were outpatients with HFmrEF (EF 
= 40-49%, n=380, 58%) or HFpEF (EF >50%, n=270, 42%), who reported at least two NT-
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proBNP measurements, and thus, were included in the study. If a patient reported more than 
one NT-proBNP measurement at the follow-up, the value recorded at the closest visit to 6 
months of follow-up from the first registration was used.
Endpoints
Endpoints were:
•	 Time to all-cause death
•	 Time to HF hospitalization
•	 Time to all-cause death or HF hospitalization (composite outcome)
The index date was defined as the outpatient clinic visit for HF, occurring between 2000 and 
December 31, 2012, at which the second NT-proBNP measurement was performed. End of 
follow-up was December 31, 2012.
Study II
Aim
To evaluate whether a reduction of NP (BNP/NT-proBNP) levels over time is associated with 
improved prognosis in acute decompensated HFpEF.
Patients
KaRen study recruited 584 patients between 2007 and 2011. After the exclusion of those who 
had violation of eligibility criteria (29 patients), withdrew the consent (16), did not report 
baseline or follow-up BNP/NT-proBNP or died or declined follow-up at 4-8 weeks (178), 
361 patients were considered for the current analysis. 
Endpoints
Endpoints were:
•	 Time to all-cause mortality or HF hospitalization (composite outcome)
•	 Time to all-cause mortality
Outcomes were adjudicated and defined according to the clinical judgment by the local 
investigators. End of follow-up was November 15th, 2012. The index date was defined as the 
4-8 weeks follow-up visit at which the second NP measurement was performed.
Statistics in Studies I-II
Change in NP levels was calculated as the percent variation between the two measurements 
(%ΔNT-proBNP or BNP =[final NTproBNP or BNP − baseline NT-proBNP or BNP]/ baseline 
NT-proBNP or BNP*100).
Baseline characteristics of patients at the time of the first NP measurement were compared 
by t or Kruskal-Wallis tests (continuous variables) or χ2 test (categorical variables) in those 
who reported an increase versus a reduction in NP levels.
The association between change in NP levels and outcomes was assessed as follows:
•	 change in NP was considered as a continuous variable, thus restricted cubic splines 
were fitted to flexibly model potential non-linearity
         Natriuretic peptides for trial design in HF
21
•	 change in NP was considered as a categorical variable (increase/decrease, with in-
crease as reference), thus Kaplan-Meier curves were fitted and adjusted proportional 
hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated by Cox 
regression models
•	 the study cohort was divided in four groups according to the median NP value at 
baseline and at follow-up: low levels at baseline and at follow-up (stable low levels), 
low at baseline and high at follow-up (increase in NP levels), high at baseline and 
low at follow-up (decrease in NP levels), and high at baseline and high at follow-up 
(stable high levels; reference group). Kaplan-Meier curves were fitted and adjusted 
proportional HR with 95% CI were calculated by Cox regression models.
Multivariable logistic regression models, using a decrease in NP as dependent variable, were 
performed to identify the independent predictors of a reduction in NP levels.
All the multivariable Cox regression/logistic regression models reported in the current 
analyses were adjusted for the variables that correlated with at least one outcome/dependent 
variable at the univariate analysis with a p-value <0.05 (marked with * in the tables reporting 
baseline characteristics of Studies I and II). 
To address the presence of missing data in multivariable models, multiple imputation using 
chained equations method (n=10) was performed in Study I, whereas in Study II the mode 
was used to replace missing values for categorical and the mean for continuous variables, 
since the amount of missing data was limited.  
A p-value<0.05 was considered statistically significant.
Statistical analyses were performed by Stata 14.2 (StataCorp LLC, College Station, Texas, 
USA) or IBM SPSS Statistics 24.0 (IBM Corp, Armonk, NY, USA). 
Study III
Aim
To compare in HFpEF vs. HRmrEF vs. HFrEF
•	 NT-proBNP levels and assess the independent determinants of high NT-proBNP 
•	 the prognostic role and discriminatory power of NT-proBNP levels 
Patients
In SwedeHF, between May 11th 2000 and December 31th 2012, 80,772 registrations were 
recorded from 51,060 unique patients. A number of 9,847 outpatients with NT-proBNP 
assessment available, no missing value for EF and follow-up ≥1 day were included in the 
study. When a patient reported more than one registration, the first including a NT-proBNP 
assessment was selected.
Endpoints
Endpoints were:
•	 Time to all-cause mortality
•	 Time to all-cause mortality or HF hospitalization
End of follow-up was December 31, 2012.
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Statistics
High vs. low NT-proBNP levels were defined according to the different median values of NT-
proBNP in HFpEF, HFmrEF and HFrEF. Baseline characteristics were compared in patients 
with high (> median value) vs. low (≤ median value) NTproBNP in HFpEF vs. HFmrEF vs. 
HFrEF by t-test or analysis of variance (ANOVA) or Wilcoxon-Mann-Whitney or Kruskal-
Wallis tests for continuous variables and by chi-squared for categorical variables.
In order to assess the different determinants of high NT-proBNP levels in HFpEF vs. 
HFmrEF vs. HFrEF, multivariable logistic regressions using high NT-proBNP levels as 
dependent variable and 32 variables as covariates were run. As consistency analysis, we 
investigated the potentially different impact of atrial fibrillation type on NT-proBNP levels 
across EF categories. Thus, multivariable models were performed including atrial fibrillation 
categorized as no vs. paroxysmal vs. permanent atrial fibrillation [8,751 patients (89% of 
the overall cohort) with known atrial fibrillation status and ECG collected were considered 
(those with pacemaker rhythm were excluded)].
The relationship between NT-proBNP and time-to-outcomes was assessed within each EF 
group using > vs. ≤ median NT-proBNP or modelling NT-proBNP as a quantitative predictor 
of events using restricted cubic splines (3 knots at fixed percentile of the distribution) to 
flexibly model potential non-linearity. 
In both logistic and survival models, statistical interactions with EF were tested using a Wald-
type test since the aim of all the analyses was to perform a comparison across EF categories 
for predictors of high NT-proBNP levels and prognosis.
To address the presence of missing data in multivariable models, multiple imputation using 
chained equations method (n=10) was performed.
In order to assess the discriminatory power of NT-proBNP in HFpEF vs. HFmrEF vs. 
HFrEF, receiver operating characteristic (ROC) curves were fitted and areas under the curves 
calculated.
A p-value<0.05 was considered statistically significant.
Statistical analyses were performed by Stata 14.2 (StataCorp LLC, College Station, Texas, 
USA) or IBM SPSS Statistics 24.0 (IBM Corp, Armonk, NY, USA). 
Study IV
Aim
To evaluate in HFpEF, HFmrEF and HFrEF, and in relevant subgroups:
•	 the association between NT-proBNP levels and CV and non-CV outcomes
•	 the association between HF treatments and CV and non-CV outcomes according to 
NT-proBNP levels
Patients
In SwedeHF, between May 11th 2000 and December 31th 2012, 80,772 registrations were 
recorded from 51,060 unique patients. Consequently, 15,849 patients with no missing values 
for EF, NT-proBNP concentration and with a follow-up ≥1 day were enrolled. When a patient 
reported more than one registration, the first including a NT-proBNP assessment was selected.
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Endpoints
Endpoints were:
•	 Time to first CV event
•	 Time to first non-CV event
End of follow-up was December 31, 2012.
Statistics
Baseline characteristics of patients included were reported according to EF category and 
compared by ANOVA or Wilcoxon-Mann-Whitney for continuous variables, and by chi-
squared for categorical variables. 
Kaplan Meier curves for outcomes were fitted in HFpEF, HFmrEF and HFrEF. Unadjusted 
and adjusted HRs with 95% CIs were calculated by Cox proportional hazard models. 
Univariate Poisson regression models were fitted to calculate the crude rates of CV and non-
CV events according to the continuous levels of NT-proBNP (modelled using restricted cubic 
splines with 4 knots at fixed percentiles of distribution). In this analysis, adjustments were not 
performed since the primary aim was to estimate event rates by EF and NT-proBNP “as is” 
when selected for trials where there is no adjustment in patient selection.
Adjusted Cox regression models were performed to assess the associations between HF 
therapies (ACE-Is or ARBs and beta-blockers) and outcomes according NT-proBNP levels 
(≤ or >median value). Variables used for adjustments are marked with * in the table reporting 
baseline characteristics for this study. In all the multivariate models, missing data were 
managed by multiple imputation using chained equations method (n=10).
A p-value<0.05 was considered statistically significant.
Statistical analyses were performed by Stata 14.2 (StataCorp LLC, College Station, Texas, 
USA). 
Ethical considerations
All studies were performed in accordance with good clinical practice guidelines (ICH-
GCP) and followed the recommendations of the Helsinki Declaration. In the health quality 
and research registry SwedeHF, individual patient consent is not required, but patients are 
informed of entry and allowed to opt out. Establishment of SwedeHF, its linking with the 
mentioned registries, and all the analyses reported in this thesis using SwedeHF data were 
approved by a multisite ethics committee. 
The KaRen study and the related substudies on characterization of and prognosis in acute 
decompensated HFpEF were approved by Regional Ethical Review Boards. All patients 
provided oral and written informed consent prior to study participation.
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RESULTS
Study I
Of 650 patients enrolled, 380 (58%) had HFmrEF (EF 40-49%) and 270 (42%) had HFpEF 
(EF≥50%). In the overall population, mean age was 73+12 years, 40% were women, the 
median time between first and second NT-proBNP measurement was 7 months [Interquartile 
Range (IQR): 4-13]. 
361 (55%) patients reported a decrease, whereas 289 (45%) an increase in NT-proBNP levels 
[137 (51%) vs. 133 (49%) in HFpEF, and 224 (59%) vs. 156 (41%) in HFmrEF, respectively]. 
Baseline characteristics according to NT-proBNP increase/decrease are reported in Table 2. 
Table 2. Baseline characteristics in Study I. Variables labeled with * were significantly 
associated with the risk of overall mortality or of HF hospitalization or of the composite 
outcome and were included in the Cox regression models together with percent changes in 
NT-proBNP levels. 
NYHA: New York Heart Association; EF: ejection fraction; NT-proBNP: N-terminal pro-B-type 
natriuretic peptide; SD: Standard Deviation; IQR: interquartile range; ACE-I: angiotensin 
converting enzyme inhibitor; ARB: angiotensin receptor blocker; MRA: mineralocorticoid 
receptor antagonist.
Variables NT-proBNP 
Decreased
361 pts (55%)
NT-proBNP 
Increased
289 pts (45%)
p Missing 
values
Demographics
1. Gender 0 (0)
Male 213 (59) 175 (61) 0.748 -
Female 148 (41) 114 (39)
2. Age, mean (SD), y* 72 (12) 74 (10) 0.052 0 (0)
3. Location
Outpatient physician 66 (18) 66 (23) 0.170 -
Outpatient nurse-based HF clinic 295 (82) 223 (77)
4. Specialty 130 (21)
Cardiology 114 (39) 98 (43) 0.370 -
Internal medicine or Geriatrics 178 (61) 130 (57)
5. Follow-up referral specialty* 16 (2%)
Primary care or Other care 84 (24) 86 (31) 0.058 -
Cardiology or Internal medicine 269 (76) 195 (69)
6. Follow up referral to outpatient 
HF nurse clinic
256 (72) 186 (66) 0.118 16(2%)
7. Follow up median (IQR), years 1.81 (0.74-2.93) 1.38 (0.65-2.56) 0.026 -
Clinical
8. Duration of heart failure, months* 2 (0)
<6 190 (53) 119 (41) 0.004 -
>6 170 (47) 169 (60)
9. NYHA* 58 (9)
I 47 (14) 31 (12) 0.255 -
II 169 (51) 116 (45)
III 117 (35) 109 (42)
IV 1 (0) 2 (1)
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Briefly, patients reporting a decrease vs. an increase in NT-proBNP levels had a shorter 
duration of HF, higher baseline NT-proBNP levels, were more likely to have history of 
myocardial infarction but less likely to suffer of atrial fibrillation. A larger proportion of 
patients who reported a decrease in NT-proBNP levels had HFmrEF vs. HFpEF, as compared 
with patients who showed an increase.
Table 2 continuing.
Variables NT-proBNP 
Decreased
361 pts (55%)
NT-proBNP 
Increased
289 pts (45%)
p Missing 
values
Demographics
10. EF, %*
> 50 137 (38) 133 (46) 0.045 -
40 - 49 224 (62) 156 (54)
11. Blood pressure, mean (SD), mmHg -
Systolic 131 (21) 130 (20) 0.271 8 (1)
Diastolic 74 (11) 74 (11) 0.370 7 (1)
12. Mean arterial blood pressure, 
mean (SD), mmHg*
93 (13) 93 (12) 0.984 8 (1)
13. Heart Rate, mean (SD), beats/
min
71 (15) 72 (14) 0.312 10 (1)
Laboratory Values
14. Creatinine clearance, mean 
(SD), ml/min*^
71 (31) 69 (32) 0.303 61 (9%)
15. Hemoglobin, mean (SD), g/L* 135 (16) 134 (16) 0.738 0 (0)
16. NT-proBNP, median (IQR), pg/
mL*
1,837 (964-
4,069)
1,372 (630-2,627) <0.001 0 (0)
Concomitant Medications
17. ACE-I* 228 (63) 179 (62) 0.807 0 (0)
18. ARB* 122 (34) 78 (27) 0.072 0 (0)
19. MRA 112 (31) 73 (25) 0.096 1 (0)
20. Digoxin 48 (13) 44 (15) 0.499 0 (0)
21. Diuretic* 274 (76) 225 (78) 0.574 2 (0)
22. Nitrate* 46 (13) 39 (13) 0.815 0 (0)
23. Platelet inhibitor 158 (44) 114 (39) 0.263 1 (0)
24. Oral anticoagulant 159 (44) 145 (50) 0.133 0 (0)
25. Statin 183 (51) 137 (47) 0.430 0 (0)
26. Beta-Blocker* 311 (86) 239 (83) 0.227 1 (0)
History and Comorbidity
27. Hypertension 229 (63) 165 (57) 0.107 0 (0)
28. Diabetes Mellitus* 70 (19) 68 (23) 0.211 0 (0)
29. Myocardial Infarction 124 (34) 77 (26) 0.040 0 (0)
30. Peripheral artery disease 29 (8) 16 (6) 0.276 0 (0)
31. Atrial fibrillation/flutter* 187 (51) 178 (62) 0.014 0 (0)
32. Stroke or transient ischemic 
attack incl intracranial bleed
57 (16) 53 (18) 0.401 0 (0)
33. Aortic stenosis* 27 (8) 26 (9) 0.564 0 (0)
34. Lung disease* 85 (24) 86 (30) 0.088 0 (0)
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The rate of change in risk of clinical outcomes depended on the actual values of change in 
NT-proBNP, with an inverse association for those with a decrease and a positive association 
for those with an increase in NT-proBNP levels (Figure 5)
Table 3 reports number of events and HRs (95% CIs) for the analyses assessing the 
associations between a decrease / increase in NT-proBNP levels and outcomes in the overall 
population and separately in HFpEF and HFmrEF. We reported that, after adjustments, a 
reduction in NT-proBNP levels was associated with significantly reduced risk of all-cause 
death, HF hospitalization and of the composite of all-cause mortality and HF hospitalization. 
Similar results were reported in both HFpEF and HFmrEF (Figure 6). 
Figure 5. Association between continuous percent changes in NT-proBNP from 
baseline to follow-up evaluation and risk of all-cause death, HF hospitalization and 
composite outcome. 
NT-proBNP: N-terminal pro-B-type natriuretic peptide; HF: heart failure.
Table 3. Cox regression models fitted for all-cause death, HF hospitalization and the 
composite outcome according to decreasing vs. increasing NT-proBNP levels in the 
overall cohort and in patients with HFpEF and HFmrEF, separately. 
HFpEF: heart failure with preserved ejection fraction; HFmrEF: heart failure with mid-range 
ejection fraction; NT-proBNP: N-terminal pro-B-type natriuretic peptide; HR: hazard ratio; CI: 
confidence interval.
All-cause Death HF Hospitalization Composite Outcome
No. 
(%)
HR
(95% CI)
P-value
No. 
(%)
HR
(95% CI)
P-value
No. 
(%)
HR
(95% CI)
P-value
O
ve
ra
ll
co
ho
rt
%Delta NT-proBNP<0
(361 pts, 55%)
57
(16%)
0.53
(0.36-0.77)
0.001
61
(17%)
0.41
(0.29-0.60)
<0.001
96
(27%)
0.46
(0.34-0.62)
<0.001
%Delta NT-proBNP> 0
 (289 pts, 45%)
78
(27%)
1.00
ref
86
(30%)
1.00
ref
125
(43%)
1.00
ref
H
Fp
EF
(E
F>
50
%
) %Delta NT-proBNP<0
(137 pts, 51%)
25
(18%)
0.43
(0.25-0.75)
0.003
22
(16%)
0.46
(0.26-0.83)
0.010
39
(28%)
0.49
(0.31-0.77)
0.002
%Delta NT-proBNP> 0
 (133 pts, 49%)
43
(32%)
1.00
ref
37
(63%)
1.00
ref
58
(44%)
1.00
ref
H
Fm
rE
F
(E
F4
0-
49
%
) %Delta NT-proBNP<0
(224 pts, 59%)
32
(14%)
0.53
(0.30-0.92)
0.024
39
(17%)
0.36
(0.22-0.59)
<0.001
57
(25%)
0.39
(0.26-0.59)
<0.001
%Delta NT-proBNP> 0
 (156 pts, 41%)
35
(22%)
1.00
ref
49
(31%)
1.00
ref
67
(43%)
1.00
ref
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Figure 6. Kaplan Meier curves fitted for all-cause death, HF hospitalization and the 
composite outcome according to decreasing vs. increasing in NT-proBNP levels. 
NT-proBNP: N-terminal pro-B-type natriuretic peptide; HF: heart failure.
Table 4. Cox Regression model fitted for all-cause death, HF hospitalization and the 
composite outcome according to categorical changes in NT-proBNP. 
HR: hazard ratio; CI: confidence interval; HF: heart failure.
All-cause Death HF Hospitalization Composite Outcome
No. (%) HR
(95% CI)
P
No. (%) HR
(95% CI)
P
No. (%) HR
(95% CI)
P
Low-Low
(258 pts, 40%)
27
(10%)
0.47
(0.27-0.79)
0.005
33
(13%)
0.38
(0.23-0.63)
<0.001
52
(20%)
0.44
(0.29-0.65)
<0.001
Low-High
(67 pts, 10%)
21
(31%)
1.49
(0.87-2.57)
0.15
18
(27%)
0.97
(0.56-1.68)
0.91
29
(43%)
1.11
(0.71-1.73)
0.66
High-Low
 (67 pts, 10%)
9
(13%)
0.45
(0.22-0.94)
0.033
10
(15%)
0.38
(0.19-0.76)
0.006
16
(24%)
0.39
(0.22-0.68)
0.001
High-High
(258 pts, 40%)
78
(30%)
1.00
ref
86
(33%)
1.00
ref
124
(48%)
1.00
ref
Table 4 reports number of events and HRs (95% CIs) for the analyses exploring the associations 
between the different combinations of NT-proBNP at the first and at the second assessment 
and outcomes. As compared with stable high NT-proBNP levels (i.e. above median at time 1 
and at time 2), stable low (i.e. below/equal to median at time 1 and at time 2) and a decrease 
in NT-proBNP levels (i.e. above median at time 1 and below/equal to median at time 2) were 
associated with improved all-cause death, HF hospitalization and composite outcome risk, 
whereas an increase in NT-proBNP levels (i.e. below/equal to median at time 1 and above 
median at time 2) was associated with similar risk of outcomes.
Of all the variables reported in Table 2, those independently associated with a decrease in NT-
proBNP levels were shorter HF duration (Odds Ratio [OR]: 1.63; 95% CI: 1.15 to 2.31; p=0.006), 
use of ARBs (OR: 1.66; 95% CI: 1.14 to 2.40; p=0.007), MRAs (OR: 1.59; 95% CI: 1.10 to 2.31; 
p=0.014), no history of atrial fibrillation (OR: 0.65; 95% CI: 0.46 to 0.92; p=0.016) and above 
median NT-proBNP baseline values (OR: 2.03; 95% CI: 1.42 to 2.89; p<0.001). There was a 
strong trend toward a statistically significant association between therapy with ACE-Is or ARBs 
and decrease of NT-proBNP levels (OR: 1.74; 95% CI: 0.99 to 3.07; p=0.055).
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Study II
The overall population (361 patients) had at the time of the hospital presentation a median 
age of 78 years (IQR: 72-83) and 56% were females. A proportion of 90% were in NYHA 
class III-IV. Median EF was 55% (IQR: 50-60), median BNP was 555 ng/l (IQR: 298 – 1,266; 
collected in 45 patients) and median NT-proBNP was 2,331 (IQR: 1,217 – 4,465; collected 
in 316 patients). 
At the follow-up visit at 4-8 weeks, 267 (74%) patients reported an improvement in BNP/
NT-proBNP levels whereas 94 (26%) showed a worsening. Median change in NP levels was 
-57% (IQR: -76%, -29%) in those who showed a decrease and +55% (IQR: +23%, +96%) 
in those who showed an increase in NPs. Baseline characteristics of patients reporting an 
increase and a decrease in NP levels were similar except for heart rate that was higher in those 
showing worsening BNP/NT-proBNP levels (Table 5).
The endpoint death or death/HF hospitalization occurred in 59 (22%) and 123 (46%) 
patients, respectively, who reported a decrease and in 26 (27%) and 50 (53%) patients who 
showed an increase in NP levels. Thus, an improvement vs. a worsening in NP levels was 
not significantly associated with the risk of all-cause mortality (HR: 0.73; 95% CI: 0.46 to 
1.17) or all-cause mortality/HF hospitalization (HR: 0.81; 95% CI: 0.58 to 1.14) (Figure 7), 
although the HRs were < 1.0. 
Similar trend toward reduced risk of outcomes in patients reporting a reduction vs. an increase 
in NP levels was reported when change in BNP/NT-proBNP was considered as a continuous 
variable (Figure 8). 
When the associations between the different combinations of BNP/NT-proBNP at the first 
and at the second assessment and outcomes were analyzed, no significant differences in 
prognosis were observed among patients with stable high, stable low, increasing (low-high) 
and decreasing (high-low) BNP/NT-proBNP levels (Table 6).
The only predictor of improvement in NP levels was higher heart rate at the baseline (OR: 
1.014; 95% CI: 1.003 to 1.025).
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Table 5. Baseline characteristics in Study II. Variables labeled with * were significantly 
associated with the risk of overall mortality or of the composite of mortality and HF 
hospitalization; thus were included in Cox regression models together with changes in NP 
levels. 
NP: natriuretic peptide; NYHA: New York heart association; EF: ejection fraction; BNP: 
B-type natriuretic peptide; NT-proBNP: N-terminal pro-B-type natriuretic peptide; ACE-I: 
angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; MRA: 
mineralocorticoid receptor antagonist; SD: standard deviation.
NP Decreased
267 pts (74%)
NP Increased
94 pts (26%)
p
Demographics
1. Gender
Male 114 (42.7) 46 (48.9) 0.334
Female 153 (57.3) 48 (51.1)
2. Age, mean (SD), y* 76 (9) 77 (9) 0.266
3. Follow up median (IQR), days 598 (283 – 998) 565 (161 – 998) 0.002
Clinical
4. NYHA*
I 2 (1) 0 (0) 0.180
II 23 (9) 9 (9)
III 97 (36) 45 (48)
IV 144 (54) 40 (43)
5. EF, %* 55 (7) 57 (8) 0.091
6. Mean arterial blood pressure, mean (SD), mmHg* 102 (21) 101 (17) 0.507
7. Heart Rate, mean (SD), beats/min 86 (26) 79 (20) 0.005
8.  Tachycardia (>100 bpm) 89 (33) 24 (25) 0.196
9. Body Mass Index (kg/m2)* 29 (6) 30 (6) 0.241
Laboratory Values
10. Creatinine clearance, mean (SD), ml/min 67 (29) 62 (27) 0.196
11. Hemoglobin, mean (SD), g/L* 117 (33) 119 (29) 0.574
12. BNP, median (IQR), ng/L 744 (367 – 1307) 272 (168 – 441) <0.001
13. NT-proBNP, median (IQR), pg/mL 2740 (1430 – 5311) 1419 (791 – 2520) <0.001
Concomitant Medications
14. ACE-I 135 (49) 39 (42) 0.149
15. ARB* 66 (25) 28 (30) 0.340
16. MRA 64 (24) 26 (28) 0.489
17. Thiazide diuretic 26 (10) 8 (9) 0.839
18. Loop-acting diuretic* 219 (73) 82 (27) 0.250
19. Calcium channel blocker 71 (27) 24 (26) 0.892
20. Beta blocker* 193 (73) 73 (78) 0.335
21. Nitrate 28 (11) 11 (12) 0.703
History and Comorbidity
22. Hypertension 209 (79) 74 (79) 1.000
23. Diabetes mellitus 71 (27) 24 (25) 0.892
24. Coronary artery disease 83 (31) 28 (30) 0.897
25. Coronary revascularization 46 (18) 14 (15) 0.746
26. Cardiomyopathies* 55 (21) 26 (29) 0.144
27. Atrial fibrillation/flutter 166 (62) 63 (67) 0.456
28. Pacemaker 39 (15) 9 (10) 0.289
29. Stroke 25 (9) 14 (15) 0.175
30. Moderate or severe valvular disease 51 (19) 15 (16) 0.640
31. Renal disease 73 (27) 28 (30) 0.689
32. Chronic obstructive pulmonary disease 35 (13) 11 (12) 0.858
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Figure 7. Kaplan Meier curves fitted for all-cause death and the composite outcome 
according to decreasing vs. increasing NP levels. 
NPs: natriuretic peptides.
Figure 8. Association between continuous percent changes in NPs from baseline to 
follow-up evaluation and risk of all-cause death and of the composite outcome.
NPs: natriuretic peptides.
Table 6. Cox Regression models fitted for all-cause death and the composite outcome 
according to categorical changes in NPs. 
HR: hazard ratio; CI: confidence interval; NPs: natriuretic peptides.
All-cause Death Composite Outcome
No. (%) HR
(95% CI)
P
No. (%) HR
(95% CI)
P
Low-Low
(124 pts, 34%)
21
(17%)
0.69
(0.37-1.27)
0.26
51
(41%)
0.84
(0.56-1.26)
0.42
Low-High
(57 pts, 16%)
16
(28%)
1.26
(0.68-2.33)
0.47
31
(54%)
1.20
(0.77-1.85)
0.42
High-Low
 (57 pts, 16%)
15
(26%)
1.06
(0.55-2.04)
0.87
28
(16%)
0.95
(0.59-1.52)
0.95
High-High
(123 pts, 34%)
33
(27%)
1.00
ref
63
(36)
1.00
ref
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Study III
Of 9,847 patients, 1,811 (18%) had HFpEF (EF≥50%), 2,122 (22%) had HFmrEF (EF 40-49%) 
and 5,914 (60%) had HFrEF (EF<40%). Mean age was 70+12 years, 32% were women and 
median NT-proBNP was 1,940 pg/ml (IQR: 829-4,191). 
Median NT-proBNP in HFmrEF (1,540 pg/ml, IQR: 652-3,317) was minimally and non-
significantly higher than in HFpEF (1,428 pg/ml, IQR: 623-3,000), but considerably lower than 
in HFrEF (2,288 pg/ml, IQR: 1,022-4,835; p<0.001).
Table 7 reports baseline characteristics of the population according to high (>median value) 
vs. low (≤median value) NT-proBNP. Briefly, except for diabetes and ARBs, patients with high 
vs. low NT-proBNP were different for all baseline variables collected across the EF categories. 
In particular, patients with high NT-proBNP levels were more likely to be female, older, with 
NYHA class III-IV, lower body mass index, creatinine clearance and hemoglobin, but higher 
heart rate, more history of atrial fibrillation and more diuretic use.
Differences in baseline characteristics in Table 7 are unadjusted. In Figure 9 we reported 
adjusted ORs (95% CIs) for the associations between several baseline characteristics and NT-
proBNP levels (high NT-proBNP included in the models as dependent variable) in HFpEF vs. 
HFmrEF vs. HFrEF. We also included a p-value for interaction between each variable and EF 
categories. 
Atrial fibrillation was associated with increased risk of having high NT-proBNP regardless of 
EF, but the OR was significantly higher in HFpEF and HFmrEF vs. HFrEF. When the type of 
atrial fibrillation (paroxysmal, permanent) was compared to no atrial fibrillation, permanent and 
paroxysmal atrial fibrillation independently predicted high NT-proBNP in HFpEF (OR: 4.67, 
95% CI: 3.59 – 6.09; OR: 1.65, 95% CI: 1.15 – 2.36, respectively) and in HFmrEF (OR: 3.30, 
95% CI: 2.57 – 4.23; OR: 1.94, 95% CI: 1.36 – 2.75), but with higher OR for permanent vs. 
paroxysmal atrial fibrillation. On the other hand, in HFrEF permanent but not paroxysmal vs. 
no atrial fibrillation independently predicted high NT-proBNP levels (OR: 1.52, 95% CI: 1.29 
– 1.80; OR: 1.03, 95% CI: 0.83 – 1.27)(p for interaction for HFpEF vs. HFmrEF vs. HFrEF 
<0.001). Other variables that differently predicted high NT-proBNP levels were hypertension 
and diabetes, with ORs significantly higher in HFmrEF vs. HFpEF and HFrEF. Additionally, 
although without any interaction with EF categories, older age (>75 years), body mass index 
≤30 and heart rate ≥70 bpm were significantly associated with the likelihood of having high 
NT-proBNP in HFmrEF and HFrEF but not in HFpEF where their role was neutral. NYHA 
class III-IV, shorter HF duration, lower creatinine clearance, anemia and use of diuretics were 
similarly associated with the risk of high NT-proBNP across the EF categories.
Table 8 reports the HRs (95% CIs) and number of events for the outcomes all-cause death and 
the composite of all-cause death and HF hospitalization in high vs. low NT-proBNP levels 
stratified by EF category. High vs. low NT-proBNP was associated with higher risk of all-cause 
death and of the composite outcome regardless of EF. In particular, for the composite outcome 
high NT-proBNP predicted higher risk of events in HFmrEF and HFpEF vs. HFrEF (Figure 
10). This was not the case for all-cause mortality where there was no interaction between NT-
proBNP levels and EF categories. Similarly, when the relationship between continuous levels of 
NT-proBNP and outcomes was analyzed, a strong positive dose-response association between 
NT-proBNP values and risk of outcomes was reported regardless of EF, but high levels of NT-
proBNP were associated with a greater increase in risk of the composite outcome, but not of 
mortality alone, in HFpEF and HFmrEF vs. HFrEF (Figure 10).
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NT-proBNP as a continuous variable had good prognostic discrimination for both outcomes. 
Overall, the area under the curve for all-cause mortality and all-cause mortality/HF 
hospitalization was largest in HFmrEF (Figure 11) in the overall population, whereas HFmrEF 
and HFpEF but not HFrEF reported lower area under the curve in atrial fibrillation vs. sinus 
rhythm (Figure 12).
Table 8. Cox Regression models fitted for all-cause death and the composite of all-
cause death and HF hospitalization according to high vs. low NT-proBNP levels in 
HFpEF vs. HFmrEF vs. HFrEF. 
High/low NT-proBNP levels were defined as > / ≤ median NT-proBNP values in HFpEF 
(1,428 pg/ml), HFmrEF (1,540 pg/ml) and HFrEF (2,288 pg/ml). For all-cause mortality: 
unadjusted p for interaction = 0.22, adjusted p for interaction = 0.68; for the composite 
outcome: unadjusted p for interaction = 0.0001, adjusted p for interaction: 0.0005. 
NT-proBNP: N-terminal pro-B-type natriuretic peptide; HFpEF: heart failure with preserved 
ejection fraction; HFmrEF: heart failure with mid-range ejection fraction; HFrEF: heart failure 
with reduced ejection fraction; HR: hazard ratio; CI: confidence interval.
All-cause Death Composite Outcome
No. 
(%)
Unadj. HR
(95% CI)
P-value
Adj. HR
(95% CI)
P-value
No. 
(%)
Unadj. HR
(95% CI)
P-value
Adj. HR
(95% CI)
P-value
H
Fp
E
F
High NT-proBNP levels
(905 pts, 50%)
299
(33%)
2.70
(2.23-3.28)
<0.001
1.90
(1.55-2.32)
<0.001
407
(45%)
2.29
(1.95-2.68)
<0.001
1.86
(1.58-2.18)
<0.001
Low NT-proBNP levels
 (906 pts, 50%)
156
(17%)
1.00
ref
1.00
ref
247
(27%)
1.00
ref
1.00
ref
H
Fm
rE
F
High NT-proBNP levels
(1,061 pts, 50%)
331
(31%)
3.27
(2.67-4.00)
<0.001
1.87
(1.52-2.31)
<0.001
512
(48%)
2.75
(2.36-3.20)
<0.001
2.00
(1.71-2.34)
<0.001
Low NT-proBNP levels
 (1,061 pts, 50%)
132
(12%)
1.00
ref
1.00
ref
246
(23%)
1.00
ref
1.00
ref
H
Fr
E
F
High NT-proBNP levels
(2,956 pts, 50%)
860
(29%)
2.67
(2.37-3.01)
<0.001
1.73
(1.53-1.97)
<0.001
1,496
(51%)
1.89
(1.75-2.05)
<0.001
1.48
(1.36-1.61)
<0.001
Low NT-proBNP levels
 (2,958 pts, 50%)
393
(13%)
1.00
ref
1.00
ref
996
(34%)
1.00
ref
1.00
ref
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Figure 10. Outcome analysis.
Panel A. Kaplan–Meier curves fitted for all-cause death and the composite outcome 
(all-cause death / HF hospitalization) in patients with high vs. low NT-proBNP levels 
and different EF categories.
Panel B. Association between continuous NT-proBNP levels and risk of all-cause 
death and of the composite outcome in the different EF categories.
High/low NT-proBNP levels were defined as > / ≤ median NT-proBNP values in HFpEF 
(1,428 pg/ml), HFmrEF (1,540 pg/ml) and HFrEF (2,288 pg/ml). 
NT-proBNP: N-terminal pro-B-type natriuretic peptide; HFpEF: heart failure with preserved 
ejection fraction; HFmrEF: heart failure with mid-range ejection fraction; HFrEF: heart failure 
with reduced ejection fraction; HR: hazard ratio.
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Figure 11. ROC curves and areas under the curves for NT-proBNP levels using all-
cause death and the composite of all-cause death and HF hospitalization as out-
comes in the different EF categories. 
NT-proBNP: N-terminal pro-B-type natriuretic peptide; ROC: receiver operating 
characteristics; AUC: area under the curve; HFpEF: heart failure with preserved ejection 
fraction; HFmrEF: heart failure with mid-range ejection fraction; HFrEF: heart failure with 
reduced ejection fraction. 
Figure 12. ROC curves and areas under the curves for NT-proBNP levels using all-
cause death the composite of all-cause death and HF hospitalization as outcomes in 
the different EF categories according to the presence/absence of concomitant atrial 
fibrillation. 
NT-proBNP: N-terminal pro-B-type natriuretic peptide; ROC: receiver operating 
characteristics; AUC: area under the curve; HFpEF: heart failure with preserved ejection 
fraction; HFmrEF: heart failure with mid-range ejection fraction; HFrEF: heart failure with 
reduced ejection fraction.
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Study IV
Out of 15,849 patients included, 23% had HFpEF, 21% HFmrEF and 56% HFrEF.
In the overall population, mean age was 73+12 years, 36% were female, median NT-
proBNP was 2,640 [IQR :1,140-5,914] pg/ml. Table 9 reports patients’ characteristics 
by EF category. HFmrEF was intermediate between HFpEF and HFrEF for age, gender, 
renal disease, hypertension, anemia, atrial fibrillation, valvular disease, lung disease, use 
of ACE-Is or ARBs, of beta-blockers and nitrates; more similar to HFpEF for body mass 
index, arterial blood pressure, prevalence of cancer, HF duration and use of MRAs; more 
similar to HFrEF for ischemic heart disease, use of platelet inhibitors, diuretics and statins. 
There were no differences across EF categories in prevalence of diabetes, use of digoxin 
and oral anticoagulants (Table 9).
Median NT-proBNP values in HFpEF (2,037 pg/ml, IQR:912-4,420) and HFmrEF (2,192, 
IQR:930-4,899) were similar and much lower than in HFrEF (3,141, IQR:1,370-7,080)
(Figure 13).
Figure 14 reports the risk of CV and non-CV events across the EF categories. In particular, 
risk of CV events was higher in HFrEF vs. HFpEF and HFmrEF, whereas the risk of non-CV 
events was highest in HFpEF, intermediate in HFmrEF and lowest in HFrEF.
Figure 15 reports the associations between NT-proBNP and CV/non-CV outcomes in HFpEF 
vs. HFmrEF vs. HFrEF. Crude rates for CV and non-CV events ranged 20-160 and 30-100 
per 100 patient-years in HFpEF, 20-130 and 20-100 in HFmrEF, 20-110 and 20-50 in HFrEF, 
respectively. 
Overall, event rates for both CV and non-CV events increased together with increasing NT-
proBNP in all EF categories, but with some differences: 1) rates for non-CV events were 
higher in HFpEF and HFmrEF vs. HFrEF regardless of NT-proBNP levels; 2) CV event 
rates increased with increasing NT-proBNP more steeply than non-CV event rates in all EF 
groups, but the increase occurred at lower NT-proBNP levels in HFpEF vs. HFmrEF vs. 
HFrEF and was steeper at lower NT-proBNP and flatter at higher NT-proBNP; 3) CV to 
non-CV event ratio increased with increasing NT-proBNP levels in HFpEF and HFrEF, but 
in HFmrEF the ratio increased at lower NT-proBNP levels and then remained almost stable 
at higher NT-proBNP levels. 
Therapy with ACE-I/ARB was significantly associated with reduced risk of CV and also 
non-CV events in HFmrEF and HFrEF, but only of CV events in HFpEF. Beta-blockers were 
significantly associated with reduced risk of CV and also non-CV events in HFmrEF, but 
only of CV events in HFrEF. In HFpEF, therapy with beta-blocker was associated with no 
change in risk of neither CV or non-CV events (Figure 16).
The associations between therapy with ACE-Is/ARBs or with beta-blockers and outcomes 
(both CV and non-CV) reported in the overall population were consistent in patients with 
NT-proBNP ≤ and > median regardless of EF category (p for interaction non-significant)
(Figure 17 and 18).
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Table 9. Baseline characteristics in Study IV. 
NYHA: New York heart association; NT-proBNP: N-terminal pro-B-type natriuretic 
peptide; ACE-I: angiotensin converting enzyme inhibitor; ARB: angiotensin 
receptor blocker; MRA: mineralocorticoid receptor antagonist; ICD: implantable 
cardioverter defibrillator; CRT: cardiac resynchronization therapy; hb: hemoglobin; 
TIA: transient ischemic attack; SD: standard deviation; HFpEF: heart failure with 
preserved ejection fraction; HFmrEF: heart failure with mid-range ejection fraction; 
HFrEF: heart failure with reduced ejection fraction; IQR: interquartile range.
Variables
HFpEF 
(n=3,623; 23%)
HFmrEF 
(n=3,322; 21%)
HFrEF 
(n=8,904; 56%) p-value
Investigated subgroups
Location*
Inpatient 1,960 (54%) 1,383 (42%) 3,645 (41%)
<0.001
Outpatient 1,663 (46%) 1,939 (58%) 5,259 (59%)
Atrial fibrillation* 2,360 (65%) 2,011 (60%) 4,566 (51%) <0.001
Renal function*
Creatinine clearance <60 ml/min 1,931 (58%) 1,510 (50%) 3,785 (45%)
<0.001
Creatinine clearance >60 ml/min 1,385 (42%) 1,521 (50%) 4,632 (55%)
Age*
>75 years 2,890 (80%) 2,310 (70%) 5,163 (58%)
<0.001
<75 years 733 (20%) 1,012 (30%) 3,741 (42%)
Gender*
Male 1,690 (47%) 2,041 (61%) 6,476 (73%)
<0.001
Female 1,933 (53%) 1,281 (39%) 2,428 (27%)
Ischemic heart disease* 1,564 (44%) 1,725 (53%) 4,627 (54%) <0.001
Diabetes* 994 (27%) 925 (28%) 2,449 (27%) 0.92
Duration of HF, months*
<6 1,640 (45.5%) 1,521 (46.0%) 4,366 (49.2%)
<0.001
>6 1,961 (54.5%) 1,789 (54.0%) 4,504 (50.8%)
Demographics
Age, mean (SD), y 77 (11) 74 (12) 71 (12) <0.001
Specialty*
Internal medicine or Geriatrics 1,333 (44%) 1,222 (41%) 3,072 (36%)
<0.001
Cardiology 1,730 (56%) 1,761 (59%) 5,474 (64%)
Follow-up referral specialty*
Cardiology or Internal medicine 1,700 (49%) 2,015 (64%) 6,638 (77%)
<0.001
Primary care or Other care 1,756 (51%) 1,152 (36%) 1,941 (23%)
Follow-up referral to outpatient HF nurse 
clinic* 1,187 (34%) 1,493 (47%) 4,931 (57%) <0.001
Year of registration*
2001-2009 1,669 (46%) 1,557 (47%) 4,197 (47%)
0.55
2010-2012 1,954 (54%) 1,765 (53%) 4,707 (53%)
Clinical
NYHA class*
I 375 (15.5%) 341 (13.1%) 600 (8.1%)
<0.001
II 1,119 (46.2%) 1,372 (52.8%) 3,330 (45.2%)
III 869 (35.9%) 827 (31.8%) 3,154 (42.8%)
IV 60 (2.5%) 59 (2.3%) 280 (3.8%)
Body mass index, mean (SD), kg/m2* 27.9 (6.2) 27.6 (5.8) 26.7 (5.3) <0.001
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Table 9 continuing.
Variables
HFpEF 
(n=3,623; 23%)
HFmrEF 
(n=3,322; 21%)
HFrEF 
(n=8,904; 56%) p-value
Investigated subgroups
Location*
Blood pressure, mean (SD), mmHg
Systolic 132 (21) 130 (21) 123 (20) <0.001
Diastolic 73 (12) 74 (12) 73 (12) 0.008
Mean arterial blood pressure, mean (SD), 
mmHg* 93 (13) 92 (13) 90 (13) <0.001
Heart rate, mean (SD), beats/min* 73 (15) 73 (15) 74 (15) <0.001
Laboratory values
NT-proBNP, median (IQR)*, pg/ml 2,037 (912, 4,420)
2,192 
(930, 4,899)
3,141 
(1,370, 7,080) <0.001
Creatinine clearance, mean (SD), ml/min 61 (30) 67 (33) 70 (34) <0.001
Hb, mean (SD), g/l 128 (17) 132 (17) 135 (17) <0.001
Treatments
ACE-I or ARB* 2,766 (76%) 2,868 (86%) 8,262 (93%) <0.001
Digoxin* 656 (18%) 545 (16%) 1,480 (17%) 0.088
Diuretic* 3,113 (86%) 2,553 (77%) 7,219 (81%) <0.001
Nitrate* 596 (16%) 510 (15%) 1,207 (14%) <0.001
Platelet inhibitor* 1,550 (43%) 1,558 (47%) 4,278 (48%) <0.001
Oral anticoagulant* 1,500 (42%) 1,396 (42%) 3,786 (43%) 0.53
Statin* 1,443 (40%) 1,567 (47%) 4,313 (49%) <0.001
Beta-blocker* 2,879 (80%) 2,850 (86%) 8,118 (91%) <0.001
MRA* 1,078 (30%) 932 (28%) 3,408 (38%) <0.001
Device therapy*
No 3,562 (99%) 3,208 (97%) 8,040 (91%)
<0.001
CRT-P 13 (0.4%) 33 (1.0%) 250 (2.8%)
CRT-D 8 (0.2%) 21 (0.6%) 283 (3.2%)
ICD 26 (0.7%) 45 (1.4%) 283 (3.2%)
Comorbidities
Smoking*
Never 1,461 (51%) 1,232 (45%) 3,027 (40%)
<0.001Previous 1,132 (40%) 1,177 (43%) 3,396 (45%)
Current 243 (9%) 300 (11%) 1,145 (15%)
Hypertension* 2,646 (73%) 2,176 (65%) 5,053 (57%) <0.001
Coronary revascularization* 787 (22%) 1,073 (32%) 2,908 (33%) <0.001
Peripheral artery disease* 366 (10%) 368 (11%) 843 (9%) 0.028
Stroke/TIA* 708 (19%) 552 (17%) 1,368 (15%) <0.001
Anemia* 1,412 (39%) 1,157 (35%) 2,635 (30%) <0.001
Valvular disease* 1,166 (33%) 804 (25%) 1,851 (21%) <0.001
Lung disease* 1,108 (31%) 940 (28%) 2,229 (25%) <0.001
Cancer within 3 years* 551 (15%) 482 (15%) 1,051 (12%) <0.001
Socio-economics
Family type*
Living alone 2,022 (56%) 1,671 (50%) 4,272 (48%)
<0.001
Married/cohabitating 1,596 (44%) 1,649 (50%) 4,601 (52%)
Education*
Compulsory school 1,831 (51%) 1,552 (47%) 3,890 (44%)
<0.001Secondary school 1,247 (35%) 1,227 (37%) 3,503 (40%)
University 503 (14%) 520 (16%) 1,418 (16%)
Income below median* 2,120 (59%) 1,697 (51%) 4,057 (46%) <0.001
Number of children, mean (SD)* 2.0 (1.4) 2.0 (1.4) 2.0 (1.4) 0.001
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Figure 13. NT-proBNP levels according to the EF category. 
NT-proBNP: N-terminal pro-B-type natriuretic peptide; HFpEF: heart failure with 
preserved ejection fraction; HFmrEF: heart failure with mid-range ejection fraction; 
HFrEF: heart failure with reduced ejection fraction.
Figure 14. Kaplan Meier curves fitted for first CV (A) and non-CV (B) event 
according to the EF category. 
CV: cardiovascular; HFpEF: heart failure with preserved ejection fraction; HFmrEF: 
heart failure with mid-range ejection fraction; HFrEF: heart failure with reduced 
ejection fraction; HR: hazard ratio; CI: confidence interval.
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Figure 15. Association between continuous NT-proBNP levels and risk of outcomes 
in the different EF categories. The histogram reports the distribution of patients according 
to the NT-proBNP levels. 
HFpEF: heart failure with preserved ejection fraction; HFmrEF: heart failure with mid-range 
ejection fraction; HFrEF: heart failure with reduced ejection fraction; NT-proBNP: N-terminal 
pro-B-type natriuretic peptide.
Figure 16. Associations between HF therapies and outcomes by EF category. HFpEF: 
heart failure with preserved ejection fraction; HFmrEF: heart failure with mid-range ejection 
fraction; HFrEF: heart failure with reduced ejection fraction; HR: hazard ratio; CI: confidence 
interval; CV: cardiovascular; ACE-I: angiotensin converting enzyme inhibitor; ARB: 
angiotensin receptor blocker.
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We explored the following subgroups: inpatients/outpatients, atrial fibrillation, creatinine 
clearance <60/≥60 ml/min, age ≥75/<75 years, gender, ischemic heart disease, diabetes, HF 
duration ≥6/<6 months. 
The risk of CV events was increased regardless of EF in patients with vs. without atrial 
fibrillation, ischemic heart disease, renal disease and diabetes. Age ≥ vs. <75 years and 
female vs. male sex were associated with lower risk of CV events in HFrEF but not in HFpEF 
and HFmrEF, even though there was no significant interaction between these subgroups and 
EF category. In all EF categories, inpatients had higher risk of CV and non-CV events as 
compared to outpatients, but with higher risk of CV events in HFpEF vs. HFmrEF vs. HFrEF 
and higher risk of non-CV events in HFpEF and HFmrEF vs. HFrEF. Overall, the risk of non-
CV events was higher in HFrEF with vs. without atrial fibrillation and age ≥75 vs. <75 years, 
creatinine clearance <60 vs. ≥60 ml/min (even though the association was still significant 
after adjustments only in HFrEF), in HFmrEF and HFrEF women vs. men and diabetes vs. 
no diabetes. However, although these subgroups were significantly associated with prognosis 
in some EF categories but not all, there was no significant interaction with EF. Longer HF 
duration (≥ vs. <6 months) predicted higher risk of CV events in HFmrEF and HFrEF and of 
non-CV events only in HFrEF.
In all subgroups, regardless of EF, crude CV event-rates were higher than non-CV event rates 
throughout the NT-proBNP range. Consistent with the main analysis, CV and non-CV event 
rates increased mostly at lower NT-proBNP levels in HFpEF vs. HFmrEF vs. HFrEF, but the 
splines for CV and non-CV event rates diverged at lower NT-proBNP in HFrEF vs. HFpEF 
and HFmrEF. In high risk profile patients (i.e. patients with atrial fibrillation, ischemic heart 
disease and diabetes, age ≥ years, males, inpatients, creatinine clearance <60 ml/min and in 
HF duration ≥6 months), increasing NT-proBNP was associated with a more rapid increase in 
both CV and non-CV risk. Similarly, splines diverged at lower NT-proBNP levels in patients 
with higher risk (except for younger patients and those with creatinine clearance<60 ml/min 
who reported the same finding although at lower risk). Additionally, in higher risk patients, 
the increase in CV events risk was steeper than in non-CV events risk.
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DISCUSSION
Randomized controlled trials have provided evidence for effective pharmacological and 
device treatments that have significantly improved mortality/morbidity in HFrEF, but 
prognosis still remains poor 1. HFmrEF has no evidence-based therapy and constitutes a 
newly characterized and relevant population for future trials. Trials in HFpEF have failed to 
provide any effective treatment, and several concerns about their design have been raised.
The four studies included in the current thesis report evidences that may be of interest for and 
support future trial design in HF. In Study I-IV we provide data supporting the use of NPs 
as surrogate endpoints in HFpEF, HFmrEF and HFrEF phase II randomized trials, whereas 
in Study III-IV we explore the role of NT-proBNP as an eligibility criterion to enrich phase 
III trials for CV vs. non-CV events.
 
NPs as surrogate endpoints
Previous studies, post-hoc analyses from trial databases and registry-based and cohort studies, 
showed NT-proBNP levels higher in HFrEF vs. HFpEF 28-31, 69, 70, but no direct comparison 
among EF categories for NT-proBNP concentrations was performed. In Study III-IV, we 
directly compared EF categories for NT-proBNP levels in the SwedeHF, confirming NT-
proBNP levels significantly higher in HFrEF vs. HFpEF, with HFmrEF more similar to 
HFpEF. This could be potentially explained by higher end-diastolic wall stress in HFrEF 
vs. HFpEF and HFmrEF and is also consistent with higher CV risk in HFrEF compared to 
HFmrEF and HFpEF 61. We also observed higher levels of NT-proBNP in HFpEF patients 
enrolled in SwedeHF as compared with those in trials 28-30, that may be potentially addressed 
by 1) the less selective nature of SwedeHF and/or 2) the inclusion in HFpEF trials of patients 
with less severe HF, i.e. at less risk of events, that may have contributed to the lack of a 
significant difference in outcome between the experimental drugs and placebo. 
A biomarker, in order to be used as surrogate endpoint, needs to have the following 
characteristics: 1) its levels have to correlate with risk of hard events (e.g. mortality/
morbidity); 2) an improvement of its levels, induced by a treatment, is associated with a 
reduction in risk of hard outcomes.
Relationship between NT-proBNP levels and prognosis
Previous studies, mainly post-hoc analyses of randomized trials, have shown NT-proBNP 
levels to be associated with risk of mortality/moribidity (e.g. HF hospitalization) in HFpEF 
and HFrEF 28-31, 69, 70. We confirmed these findings in a large unselected cohort of HF patients, 
the SwedeHF, reporting adjusted HRs for all-cause mortality/HF hospitalization ranging 
1.48-2.00 in above vs. below/equal to median NT-proBNP levels, that is roughly comparable 
to those observed in trials such as COPERNICUS 31, Val-HeFT 69, I-PRESERVE 28, PEP-CHF 
29, and CHARM-Preserved 30 (Study III). On top of this finding, we observed that although 
NT-proBNP levels were lower in HFpEF and HFmrEF vs. HFrEF, 1) the concentration 
above vs. below/equal to median but also continuously higher levels predicted significantly 
higher risk of mortality/HF hospitalization in HFpEF and HFmrEF vs. HFrEF and 2) the 
discriminatory power of NT-proBNP was higher in HFmrEF vs. HFpEF and HFrEF. These 
results are surprising and may suggest that the same NT-proBNP concentration is associated 
with different prognosis according to the EF category (also shown in Study IV), thus different 
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cut-offs of NT-proBNP may be considered for eligibility in HFpEF vs. HFmrEF vs. HFrEF 
trials. Conversely, these findings may be also explained by HFpEF and HFmrEF patients 
with low NT-proBNP levels having mild HF or even symptoms driven by comorbidities and 
thus, being at lower risk of CV events, compared to those with higher NT-proBNP, whereas 
all HFrEF patients, regardless of NT-proBNP levels, had “true” HF. Study IV also reports a 
clear strong association between continuous NT-proBNP levels and risk of CV and non-CV 
events in HFpEF, HFmrEF and HFrEF. 
Relationship between changes in NT-proBNP levels and prognosis
A previous meta-analysis of randomized trials in HFrEF reported NT-proBNP changes from 
baseline to end of follow-up to be significantly associated with the risk of HF hospitalization 27. 
In the I-PRESERVE trial, enrolling patients with HFpEF (EF≥45%) and NYHA class II-IV, a 
decrease and increase in NT-proBNP levels <1000 pg/mL from baseline to 6-month follow-
up predicted a 27% reduction and 2-fold increase in CV death or HF hospitalization risk, 
respectively, whereas beyond a 1000 pg/mL rise or fall, there was only little additional change 
in risk 32. This analysis was performed on randomized trial data, that are highly selective and 
may not consider the heterogeneity, the competing risk and the comorbidities that characterize 
HFpEF real-world patients. Additionally, HFpEF and HFmrEF were not considered as 
distinct entities with EF=40-44% excluded from the analysis. Therefore, we investigated the 
association between changes in NT-proBNP and outcomes in 650 outpatients with HFpEF 
or HFmrEF enrolled in the SwedeHF (Study I). Notably, we reported that a decrease vs. an 
increase in NT-proBNP levels at a median time of 7 months between the two measurements 
was associated with a 51% and 61% reduction in risk of mortality/hospitalization in HFpEF 
and HFmrEF, respectively, and the risk of outcomes increased together with the continuous 
increase in NT-proBNP levels. Conversely, in Study II enrolling patients with acute 
decompensated HFpEF, we could show only a non-statistically significant 19% reduction in 
risk of mortality/HF hospitalization in those who reported a decrease vs. an increase in BNP/
NT-proBNP levels (4-8 weeks between the first and the second NP measurement). Changes 
in NPs have been demonstrated to be prognostic in acute decompensated HFrEF 71. The 
difference between acute decompensated HFpEF and HFrEF may be explained by lower NP 
levels and thus, less remarkable changes in NPs that may lead to fail to find an association 
with outcomes. Furthermore, the difference between acute decompensated and chronic 
HFpEF may be addressed by the more complex and heterogeneous population with acute 
decompensated HFpEF, together with the more important confounding effect of tachycardia, 
hypertension and acute ischemia that affects both the presentation, the levels of NPs and the 
association between these variables and the outcomes.
NT-proBNP for eligibility and enrichment in HF trials 
Higher NT-proBNP levels are associated with higher risk of outcomes (Study III-IV), thus 
enrolling patients with high NT-proBNP levels in HF trials should ensure the presence of HF 
and enrich for CV events, leading to higher chances of success for the experimental treatment, 
if the pathophysiological target is correct. HFpEF and HFmrEF vs. HFrEF exhibit different 
NT-proBNP concentration, that may be explained by higher end-diastolic wall stress in HFrEF 
vs. HFpEF and HFmrEF. Thus, a different value of NT-proBNP may be chosen for eligibility 
in trials according to the EF category (Study III-IV). Additionally, previous studies reported 
high NT-proBNP levels associated with several comorbidities, e.g. atrial fibrillation and chronic 
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kidney disease, and lower body mass 72-74. Thereby, in some cases, higher NT-proBNP could 
reflect the presence of comorbidities rather than the severity of HF, and thus different (i.e. 
higher) NT-proBNP values may be chosen as inclusion criterion in trials. In Study III we 
assessed the independent predictors of high NT-proBNP levels across the EF spectrum. We 
reported that regardless of EF category, higher age, NYHA class and heart rate, lower body 
mass index, presence of atrial fibrillation, chronic kidney disease and anemia, and diuretic use 
were independently associated with higher NT-proBNP levels. Notably, atrial fibrillation was 
associated with significantly higher NT-proBNP levels in HFpEF and HFmrEF vs. HFrEF 
independently of heart rate and use of rate control medication, that may be explained by atrial 
fibrillation, and in particular paroxysmal atrial fibrillation, contributing relatively less to filling 
pressure and wall stress in HFrEF vs. HFpEF and HFmrEF. We also observed obesity to be a 
weak predictor of NT-proBNP in HFpEF but to be strongly associated to NP levels in HFpEF. 
This may support the role for obesity as a driver for HFpEF rather than a maker of disease, 
whereas in HFmrEF and HFrEF low body mass may be linked to cachexia and thus, be tied 
to the severity of HF. All together, these findings suggest that optimal NT-proBNP cut-offs 
for eligibility in randomized trials should be carefully tailored, especially according to the EF 
category, since HFpEF, HFmrEF and HFrEF report different NT-proBNP levels and several 
differences in predictors of high NT-proBNP levels, and in specific subgroups such as in 
presence/absence of atrial fibrillation and renal disease. 
Consequently, in Study IV, we explored the relationship between continuous NT-proBNP 
levels, CV and non-CV events, according to the different EF categories and in relevant 
subgroups, in order to provide to trialists and sponsors reference data facilitating the choice 
of appropriate values for NT-proBNP for eligibility in randomized trials. Importantly, we 
evaluated the ratio CV to non-CV events ratio, since the optimal cut-off for NT-proBNP 
for eligibility and enrichment for CV events is supposed to increase the likelihood of CV 
but not of non-CV events (i.e. increase CV to non-CV event ratio) where the latter may 
not be affected by HF therapies. We reported 1) higher non-CV event rates with higher EF 
across the whole NT-proBNP spectrum; 2) that higher NT-proBNP levels as inclusion criteria 
enrich for CV events but also increase the CV to non-CV event ratio; 3) higher CV to non-
CV event ratio at lower NT-proBNP levels in HFrEF vs. HFmrEF vs. HFpEF, suggesting a 
potential optimal NT-proBNP cut-off lower in HFrEF than in HFpEF and HFmrEF; 4) that 
the trade-off with increasing NT-proBNP levels is the reduction of eligible patients and thus, 
less feasible recruitment rates and adequacy of enrollment; 5) patients at higher risk (with 
atrial fibrillation, ischemic heart disease, diabetes, renal disease, men, inpatients, longer 
HF duration) present an increase in CV and non-CV event rates and in the CV to non-CV 
event ratio (except for renal disease) at lower NT-proBNP levels. Additionally, we could not 
observe any difference in the association between ACE-I or ARB and beta-blocker therapies 
and outcomes according to NT-proBNP levels, and current literature on the topic reports 
inconsistent evidence 28, 31, 75-78. However, this last result has to be interpreted considering that 
we used observational data that cannot demonstrate any potential treatment effect because of 
unmeasured confounders.
Strengths and Limitations
Strengths of Study I, III and IV is the use of data from SwedeHF, one of the largest HF 
registries worldwide, including a large and unselected cohort of patients with HFpEF, 
HFmrEF and HFrEF, with around 80 variables recorded, linkage with other registries 
providing additional data (comorbidities, socioeconomics) and no missing data for outcomes. 
Additionally, the large sample of patients with a NT-proBNP value measured in SwedeHF 
allowed us to characterize NT-proBNP throughout the EF spectrum. Strengths of Study 
II is the availability of serial measurements of NT-proBNP/BNP in patients with acute 
decompensated HFpEF, who have been rarely investigated. 
A limitation of all the studies included in this thesis is the use of observational data that 
are subject to selection bias and confounding. Even though the analyses were extensively 
adjusted for potential confounders when needed, we cannot rule out unmeasured confounders. 
Limitations of Study I, III and IV are linked with the use of SwedeHF, that has as only 
inclusion criterion clinician-judged HF, thus some patients, in particular those with preserved 
EF, may not have HF. There are missing data for some variables, but we used multiple 
imputation to reduce the bias due to data not missing at random. Generalizability of our 
findings to other countries may depend on similarities in population characteristics, health 
care and HF management. The limited amount of longitudinal data allowed us to include only 
650 patients in Study II and did not permit us to investigate NT-proBNP levels in patients 
with increasing/decreasing EF in Study III. Furthermore, NT-proBNP is indicated in Sweden 
for diagnostic and prognostic purposes in HF but not collected for serial follow-up or guiding 
therapy. Thus, longer surviving patients may have had higher chances to get a second NT-
proBNP assessment (survival bias) and, on the contrary, deteriorating patients may have had 
greater indication to get more than one measurement (bias by indication). In addition HFpEF, 
HFmrEF and HFrEF were defined only according to the EF. Study II included a relatively 
small cohort of patients, thus we cannot rule out that with larger sample size the association 
between NT-proBNP levels and prognosis would have become statistically significant. 
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CONCLUSIONS
NT-proBNP levels are associated with prognosis across the EF spectrum (Study III-IV). A 
reduction in NT-proBNP levels is associated with improved mortality/morbidity in HFpEF 
and HFmrEF (Study I), with previous studies reporting similar findings in HFrEF 27. These 
data support the use of NT-proBNP as surrogate endpoint in phase II trials in chronic HF. 
We do not report any significant association between changes in NP and prognosis in acute 
decompensated HFpEF, but only a trend, thus further investigation in larger cohorts may be 
needed (Study II). The observed relationship between NT-proBNP levels and CV and non-
CV events supports the use of NT-proBNP for eligibility and enrichment for CV events in HF 
trials, but cut-off levels should be carefully tailored to comorbidities (Study III). The role of 
NT-proBNP in predicting potential treatment response remains unclear (Study IV).
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